首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | C5a |
| Uniprot No | P01031 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 679-751aa |
| 氨基酸序列 | LQKKIEEIAAKYKHSVVKKCCYDGACVNNDETCEQRAARISLGPRCIKAF TECCVVASQLRANISHKDMQLGR |
| 预测分子量 | 8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于C5a重组蛋白的3篇代表性文献概览：
---
1. **文献名称**：*Production of recombinant human C5a in Escherichia coli: Optimization of culture conditions*
**作者**：Zhang Y, et al.
**摘要**：该研究通过优化大肠杆菌表达系统(如诱导温度、IPTG浓度等)，成功制备了高纯度重组人C5a蛋白，并验证其通过趋化实验和钙流检测的生物活性，为大规模生产功能性C5a提供技术参考。
---
2. **文献名称**：*Structural and functional characterization of recombinant mouse C5a*
**作者**：Klos A, et al.
**摘要**：研究利用哺乳动物细胞表达系统制备重组小鼠C5a，结合晶体结构解析和受体结合实验，揭示了C5a与其受体(C5aR1)的关键相互作用位点，并证明其在炎症模型中的促炎活性。
---
3. **文献名称**：*Targeted inhibition of C5a receptor via a novel recombinant protein attenuates sepsis-induced organ injury*
**作者**：Huber-Lang M, et al.
**摘要**：开发了一种重组C5a拮抗剂蛋白(如C5aR抑制剂)，通过阻断C5a-C5aR信号通路，显著减轻脓毒症模型中的多器官损伤，为抗炎治疗提供潜在策略。
---
(注：以上文献为示例，实际引用需以具体数据库检索结果为准。)
C5a recombinant protein is a biologically active derivative of the complement component C5a, a critical mediator of the innate immune system. Generated through the proteolytic cleavage of complement protein C5 during complement cascade activation, C5a functions as a potent anaphylatoxin and chemoattractant. It plays a central role in inflammatory responses by binding to its cognate receptor, C5a receptor 1 (C5aR1), a G protein-coupled receptor expressed on immune cells such as neutrophils, macrophages, and mast cells. This interaction triggers intracellular signaling pathways that promote chemotaxis, phagocytosis, and the release of pro-inflammatory cytokines, while also modulating adaptive immunity.
Recombinant C5a is produced using genetic engineering techniques, typically by expressing the human C5a gene in bacterial (e.g., E. coli) or mammalian cell systems. The recombinant form retains the native protein's 74-amino acid structure (77 amino acids in precursor form), including conserved disulfide bonds critical for its tertiary structure and bioactivity. Researchers often utilize it in studies investigating inflammatory diseases (e.g., sepsis, rheumatoid arthritis), immune complex disorders, and ischemia-reperfusion injury. Its controlled production enables standardized experimental conditions for dissecting C5a's dual role in host defense and pathological inflammation.
Recent applications extend to drug discovery, particularly in developing C5aR1 antagonists or anti-C5a antibodies for therapeutic intervention. However, handling requires caution due to its potent pro-inflammatory properties. Quality control measures ensure endotoxin-free preparations with verified receptor-binding capacity through in vitro bioassays. As complement-targeted therapies gain momentum, recombinant C5a remains indispensable for mechanistic studies and preclinical validation of novel immunomodulatory agents.
×
